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Extracellular RNAs (exRNAs) are present in human serum. It
remains unclear to what extent these circulating exRNAs may
reflect human physiologic and disease states. Here, we developed
SILVER-seq (Small Input Liquid Volume Extracellular RNA Sequenc-
ing) to efficiently sequence both integral and fragmented exRNAs
from a small droplet (5 µL to 7 µL) of liquid biopsy. We cali-
brated SILVER-seq in reference to other RNA sequencing methods
based on milliliters of input serum and quantified droplet-to-
droplet and donor-to-donor variations. We carried out SILVER-
seq on more than 150 serum droplets from male and female
donors ranging from 18 y to 48 y of age. SILVER-seq detected
exRNAs from more than a quarter of the human genes, includ-
ing small RNAs and fragments of mRNAs and long noncoding
RNAs (lncRNAs). The detected exRNAs included those derived
from genes with tissue (e.g., brain)-specific expression. The exRNA
expression levels separated the male and female samples and
were correlated with chronological age. Noncancer and breast
cancer donors exhibited pronounced differences, whereas donors
with or without cancer recurrence exhibited moderate differences
in exRNA expression patterns. Even without using differentially
expressed exRNAs as features, nearly all cancer and noncancer
samples and a large portion of the recurrence and nonrecurrence
samples could be correctly classified by exRNA expression val-
ues. These data suggest the potential of using exRNAs in a single
droplet of serum for liquid biopsy-based diagnostics.
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L iquid biopsy is a rapidly expanding class of in vitro diagnostics(IVD) due to its accessibility (1). Nearly all types of molecu-
lar and cellular components in human blood have been explored
as candidate targets for IVD development. These include cir-
culating tumor cells, exosomes, extracellular proteins, peptides,
hormones, metabolites, extracellular DNA and their methy-
lated and hydroxymethylated forms, and extracellular RNAs
(exRNAs) (2, 3).
A variety of exRNAs have been detected in human plasma
and serum (4, 5). Small exRNAs including micro RNAs
(miRNAs) have been correlated with clinical outcomes (6, 7).
Less is known about the existence of other types of exRNAs
and their relevance to clinical outcomes (4). To effectively
analyze exRNA, we developed a low-input exRNA sequenc-
ing technology called Small Input Liquid Volume Extracel-
lular RNA Sequencing (SILVER-seq). SILVER-seq takes as
few as several microliters of serum as input. This volume is
smaller than the typical yield of a finger prick, which is approx-
imately 30 µL of blood. Based on the serum samples collected
by the Predictors of Ovarian Insufficiency in Young Breast
Cancer Patients study (8), we assessed the size distribution
of serum exRNAs, carried out exRNA sequencing from over
130 serum samples, and assessed the correlations of different
classes of serum exRNAs with physiological factors and clinical
outcomes.
Results
Concentration and Size Distribution of exRNA in Human Serum. We
started by measuring the range of concentrations and sizes of
exRNA in human serum. To this end, we analyzed 10 serum
samples. To account for technical variability, we purified exRNA
with 4 different RNA purification kits, including exoRNeasy,
TRIzol LS, NORGEN, and QIAzol, and subsequently quanti-
fied them with a bioanalyzer. The measured exRNA concen-
trations ranged from 0.3 ng/mL to 4.2 ng/mL in these serum
samples (SI Appendix, Fig. S1A). Most detected exRNA are
within the size range of 20 nucleotides (nt) to 200 nt (SI
Appendix, Fig. S1B). These data suggest that the exRNA con-
centrations are approximately several nanograms per milliliter
and are either small RNAs or fragmented long RNAs in hu-
man serum.
SILVER-seq for exRNA Sequencing. We developed the SILVER-seq
technique for exRNA sequencing, by adapting the major steps of
single-cell RNA sequencing that also dealt with a small amount
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of input materials (9, 10). Unlike other liquid biopsy RNA
sequencing (RNA-seq) methods, SILVER-seq does not start
with RNA purification, because this would cause the loss of most
RNA from the very small amount of serum. Instead, SILVER-
seq involves adding library preparation reagents directly into the
original liquid sample (SI Appendix, Fig. S2).
To test whether SILVER-seq could reliably produce sequenc-
ing libraries from microliters of human serum, we split a serum
sample into 8 aliquots, with the volumes of 3, 5, 6, and 7 µL,
respectively, in replicates. The final sequencing libraries ranged
in fragment size from approximately 200 base pairs (bp) to 300 bp
(Fig. 1A). This size range was consistent with the expectation,
considering the 20- to 200-nt exRNA plus several nucleotides
of template switching oligos and 2 sequencing adaptors total-
ing 132 bp. We sequenced the 8 libraries to yield an average of
4.8 million single-end sequencing reads per library. More than
80% of the reads from each library were uniquely mapped to
A
B
C
Fig. 1. SILVER-seq sequencing libraries. (A) Size distribution of SILVER-seq
constructed sequencing library from each serum aliquot (column), indexed
by 1 to 8 (Aliquot #). Volume (microliters) is the volume of each aliquot.
(B) Percentage of uniquely mapped reads of the corresponding library
(column). (C) Number of exRNAs with 5 or more TPM in each library
(column).
the human genome (hg38) (Fig. 1B). These data suggest that
SILVER-seq could consistently generate sequencing libraries
from a few microliters of human serum.
Sensitivity Analysis of Input Volumes. To evaluate the impact of
input volume on the quality of the sequencing library, we used
the sequence mapping rate and the number of mapped exRNAs
as 2 metrics to reflect the quality of a sequencing library. While
5 µL to 7 µL of input (aliquots 3 to 8) resulted in 80% or higher
mapping rates and similar numbers of mapped exRNAs, 3 µL
of input (aliquots 1 and 2) resulted in smaller mapping rates
and fewer detected exRNAs (Fig. 1 B and C). To test the donor
effect on library quality, we analyzed additional serum samples
from 2 other donors (donors 2 and 3). We split the serum from
donor 2 into four 3-µL and two 7-µL aliquots, and split the serum
from donor 3 into five 3-µL and four 7-µL aliquots, resulting in a
total of 15 serum aliquots. We constructed a SILVER-seq library
from each serum aliquot and sequenced each library to yield
approximately 5 million reads. The mapping rates from 7 µL-
derived libraries were again higher than those from 3 µL-derived
libraries (SI Appendix, Fig. S3A) with more detected exRNAs (SI
Appendix, Fig. S3B). These data from the 2 additional donors
reinforced the idea that SILVER-seq can produce sequencing
libraries from microliters of input serum, and suggest 5 µL to 7
µL as the preferred input volume for SILVER-seq.
Comparison of SILVER-seq and Standard RNA-seq. We compared
the exRNA expression profiles obtained using SILVER-seq
with those obtained using standard RNA-seq methods. The
expected amount of exRNA in 5 µL to 7 µL of serum (SILVER-
seq input volume) is approximately 10 pg, comparable to the
amount of RNA in a single cell (11). Given the poor corre-
lation between gene expression quantified by single-cell and
bulk RNA-seq (12), we did not anticipate a strong correlation
between exRNA expression levels measured from several micro-
liters of serum (SILVER-seq) and those from several milliliters
(standard RNA-seq).
We examined the overlaps of detected exRNAs between 2
experiments. To establish the exRNAs that can be detected by
2 standard RNA-seq experiments, we purified and sequenced
RNA from 2 serum samples from the same donor (RNA-seq-
1 and RNA-seq-2), which detected 2,379 and 4,500 exRNAs,
respectively, with 563 exRNAs in the intersection. Next, we
applied SILVER-seq to 7 µL of serum from the same donor.
SILVER-seq detected 20,841 exRNAs, of which 1,706 and 2,933
intersected with the exRNAs detected in RNA-seq-1 and RNA-
seq-2, respectively (SI Appendix, Fig. S4 A and B and Table S1 A
and B). A gene detected by either RNA-seq-1 or RNA-seq-2 has
a 4.5-fold increase of odds to be detected by SILVER-seq (odds
ratio = 4.5, χ2 P value < 10−32) (SI Appendix, Table S1C). Fur-
thermore, a gene detected by both RNA-seq-1 and RNA-seq-2
has a 6.9-fold increase of odds to be detected by SILVER-seq
(odds ratio = 6.9, χ2 P value< 10−32) (SI Appendix, Table S1D).
Therefore, exRNAs detected by standard RNA-seq are more
likely to be detected by SILVER-seq than those undetectable
by the standard RNA-seq. Furthermore, the exRNAs detected
by both standard RNA-seq assays are even more likely to be
detected by SILVER-seq.
Next, we compared the measured exRNA expression lev-
els. As a reference, Pearson correlation between the exRNA
expression levels derived from RNA-seq-1 and RNA-seq-2
was 0.68 (SI Appendix, Fig. S4C). In comparison, the Pear-
son correlation was 0.67 between RNA-seq-1 and SILVER-seq,
and 0.84 between RNA-seq-2 and SILVER-seq (SI Appendix,
Fig. S4C). Thus, the correlation of the measured expression
levels between SILVER-seq and a standard RNA-seq was
comparable to the correlation between 2 standard RNA-seq
methods.
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Variability of SILVER-seq Measurements among Biological Replicates.
We also assessed the variability of SILVER-seq measurements
based on 2 serum aliquots of the same donor. Considering
the stochasticity in splitting the pool of a small number of
molecules (13), we anticipated large differences between 2 serum
droplets.
We assayed two 7-µL serum aliquots with SILVER-seq and
a 1-mL serum sample from the same donor by standard RNA-
seq (SI Appendix, Fig. S4D). An exRNA detected by either
SILVER-seq assay exhibited a 6.4- and 5.5-fold increased odds
of being detected by standard RNA-seq (odds ratio = 6.4
and 5.5, χ2 P value < 10−32 for both cases) (SI Appendix,
Table S2). An exRNA detected by both SILVER-seq assays
exhibited a 6.2-fold increased odds for being detected by stan-
dard RNA-seq (odds ratio = 6.2, χ2 P value < 10−32). In
this test, SILVER-seq–detected exRNAs are more likely to
be detected by standard RNA-seq. However, adding replicate
SILVER-seq assays did not further increase overlaps with stan-
dard RNA-seq, likely reflecting droplet-to-droplet biological
variability.
Next, we compared the measured exRNA expression levels.
The Pearson correlation was 0.66 between the 2 SILVER-seq
assays, and 0.64 and 0.85 between SILVER-seq and each stan-
dard RNA-seq assay (SI Appendix, Fig. S4 C and E–G). In this
test, the correlation between 2 SILVER-seq assays was compa-
rable to the correlation between a SILVER-seq and a standard
RNA-seq.
An Estimate of Total Number of exRNAs in Serum. We tested
whether the number of detected exRNAs will increase as we
combine SILVER-seq data of serum aliquots from the same
donor. To this end, we analyzed 2 donors and prepared 15
serum aliquots from each donor. We carried out SILVER-seq
from every aliquot. The SILVER-seq of the first aliquot of each
donor was mapped to approximately 30,000 genes (SI Appendix,
Fig. S5). As we sequentially combined SILVER-seq data of
additional aliquots, these numbers increased and plateaued at
∼41,000 genes, which is 67.6% of the annotated coding and non-
coding genes of the human genome (hg38). These data suggest
that not all genes gave rise to exRNAs in serum. Each SILVER-
seq based on 7 µL of serum could detect approximately 3/4 of the
exRNAs that were detectable by pooling the SILVER-seq data
from repeated assays (SI Appendix, Fig. S5).
Presence of exRNAs Derived from Tissue-Specific Genes. We tested
whether tissue-specific gene expression contributed to exRNA
in circulation. To this end, we used previously reported genes
with tissue-specific expressions, including 176, 78, and 192 genes
that are specifically expressed in brain, peripheral nervous sys-
tem (PNS), and bone marrow, respectively (14, 15). With the
exception of 1 brain-specific and 3 bone marrow-specific genes,
exRNAs derived from all of the tissue-specific genes were
detected in all 3 donors (Fig. 2 A–C, Upper). Furthermore, the
expression levels as measured by transcripts per million (TPM)
were not concentrated near 0 (Fig. 2 A–C, Lower). Instead, the
exRNA abundances (TPM) of tissue-specific genes exhibited
unimodal distributions with positive modes (P value < 10−32,
Kolmogorov test). These distributions suggest that the tissue-
derived exRNAs are at an equilibrium state of balanced supply
and removal in serum.
Nonuniform Presence of Different Fragments of a Long RNA in Serum.
The size distribution of exRNA suggested lack of full-length
long RNA in serum (SI Appendix, Fig. S1), which raises the
question of whether different parts of a long RNA had equal
chances of being detected as exRNA. We used the KRAS onco-
gene as a test case for this question. In the 128 serum samples
in this study (SI Appendix, Fig. S6 and Table S3), a total of
6,864 reads were uniquely mapped to KRAS, in which 5,576
reads (81.2%) were derived from the fourth exon (red curve,
Fig. 2D), suggesting nonequal chances for different fragments
of the KRAS transcripts to be present in serum (q value <
10×16, Kolmogorov–Smirnov test for uniform distribution) (SI
Appendix, Fig. S7). Next, we checked whether the abundance of
Exon 4-derived exRNA was driven by a small number of serum
samples. The Exon 4-derived exRNA was detected in the major-
ity (78.1%) of the samples, whereas no other fragments of the
KRAS were detected in more than 1/3 of the samples (green
curve, Fig. 2D). In this case, the RNA fragments present in serum
were nonuniform. Certain parts of KRAS mRNA had greater
chances of presence in serum.
exRNA Reflects Sex and Chronological Age. We asked whether
exRNA correlates with sex and age, 2 most common physio-
logical parameters. We applied SILVER-seq to analyze a total
of 128 serum samples, which yielded, on average, 6.56 million
uniquely mapped reads per sample (SI Appendix, Fig. S6 and
Table S3). We plotted the normalized numbers of uniquely
mapped SILVER-seq reads to the sex chromosomes of every
serum sample (Fig. 3A). This completely separated the serum
samples of males (blue) and females (red). This separation
suggests a clear correspondence between patterns of exRNA
expression and sex.
Next, we tested whether exRNA expression reflects a donor’s
chronological age. A total of 1,149 exRNAs exhibited modest
age-associated expression changes (P value < 0.01, F test, q val-
ues of these exRNAs range from 0.00002 to 0.41033), including
mRNA- and noncoding RNA-derived exRNAs (Fig. 3 B and C).
These age-correlated exRNAs were enriched in disease classes
of substance dependence, psychological disorders, and aging
(Benjamini adjusted P value = 0.015), as well as hematologi-
cal, metabolic, and cardiovascular disorders [Benjamini-adjusted
P value = 0.10; disease class enrichment analysis by DAVID
(16)] (Fig. 3C). The exRNAs with the strongest positive corre-
lations with age included VCAN, a proteoglycan involved in cell
adhesion, MGAT4C, a glycosyltransferase required for proper
lysosomal function, and TOR1AIP2, an endoplasmic reticulum
membrane protein (SI Appendix, Fig. S8 A–C). The exRNAs
with the strongest negative correlations with age included
PRRG3, a vitamin K-dependent transmembrane protein, YBX1,
a ribonucleoprotein (RNP) involved in microRNA processing
and mRNA splicing, and FSTL3, a secreted glycoprotein that
binds and inhibits Activin A and BMP2 signals (SI Appendix,
Fig. S8 D–F). These top-ranked age-correlated exRNAs were
derived from the mRNAs of secreted or transmembrane proteins
that conjugate, bind, or modify glycans. Indeed, glycans have
been nominated as a biomarker of biological age (17). These data
suggest correlations between age-dependent circulating exRNA
changes and age-dependent gene expression changes in various
tissues.
We built a regression model using exRNA expression levels
as covariates and age as the outcome. Hereafter, we denote
the exRNA predicted age by this regression as exRNA age.
The exRNA age exhibited a Pearson correlation of 0.986
with chronological age (Fig. 3D). Approximately 95.4% of the
variation of chronological age was explained by exRNA age (P
value < 10−32, F test). The exRNA age was within 2 y range
of the chronological age for more than 90% of the samples.
We tested sex, ethnicity, body mass index, smoking status, and
drinking status as potential confounders. None of these fac-
tors exhibited any noticeable impact to the correlation between
exRNA age and chronological age (all adjusted P values > 0.9).
Taken together, exRNA age is predictive of chronological age.
The correlation of SILVER-seq data and human physiology pro-
vided a baseline for us to move on to testing SILVER-seq’s
predictive power to disease status.
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Fig. 2. Presence of exRNAs derived from genes with tissue-specific expression. (A–C) Number and expression levels of the exRNAs derived from (A) brain-,
(B) PNS-, and (C) bone marrow-specific genes. (Upper) The number of detected exRNAs in each donor. N, the total number of genes that are specifically
expressed in this tissue. (Lower) Distribution of the expression of the exRNAs derived from the corresponding tissue-specific genes. (D) Distribution of
SILVER-seq reads on all of the KRAS exons (x axis). (Upper) Cumulative read counts from all serum samples. (Lower) The number of serum samples with reads
mapped to respective KRAS exons.
Similarity of Global exRNA Profiles between Cancer and Normal Sera.
We tested whether the overall distributions of exRNAs were
different between cancer and normal sera. Our SILVER-seq
datasets included 96 serum samples of breast cancer patients
(cancer samples) (SI Appendix, Table S4) and 32 serum sam-
ples from other donors who did not have self-reported disease
(normal samples) (SI Appendix, Table S3). TPM were calcu-
lated for each exRNA and used as the surrogate metric for the
expression level of the exRNA. The distributions of TPM exhib-
ited little difference between any 2 cancer samples or between a
cancer sample and a normal sample (Fig. 4A and SI Appendix,
Fig. S9). Thus, every sample contains a similar proportion of
highly expressed exRNAs, regardless of the threshold for calling
highly expressed exRNAs.
Differentially Expressed exRNAs between Cancer and Normal Donors.
To test for differential expression of exRNAs between the
serum samples collected from cancer and normal donors, we
computed the fold change and false discovery rate (FDR)
for every exRNA (Fig. 4B). Regardless of the FDR thresh-
old, there were more exRNAs with higher expression in can-
cer (cancer-upregulated) than those with lower expression in
cancer (cancer-downregulated) as compared to normal sam-
ples (Fig. 4B). The cancer-upregulated exRNAs that were also
most frequently detected among the cancer samples that came
from RAC2, KRAS, and CAMK2A (Fig. 4 C–E). RAC2 and
KRAS are 2 members of the Ras proto-oncogene superfam-
ily, associated with breast cancer tumorigenesis and metastasis
(18) (SI Appendix, Fig. S10). The upregulation of calcium-
dependent protein kinase CAMK2A likely reflects perturbed
calcium homeostasis, a hallmark of cancer (19). The cancer-
downregulated exRNAs with the highest recurrence in nor-
mal samples were long intergenic noncoding RNA (lincRNA)
AL121652.1 and pseudogene RNA AC048346.1 (Fig. 4 F and
G). Thus, the top-ranked exRNAs came from both coding and
noncoding RNAs.
The Different Capacity of Different RNA Types in Differentiating
Cancer and Normal Serum Samples. We asked whether differ-
ent types of RNAs exhibit the same power of differentiating
cancer and normal samples. To establish a baseline, we did
a principal component analysis (PCA) using exRNAs of all
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Fig. 3. Correlations of exRNA expression with sex and age. (A) Scatter plot of normalized SILVER-seq reads mapped to X (x axis) and Y (y axis) chromosomes
of every serum sample (circle). Male and female samples are colored in blue and red, respectively. (B) Numbers of exRNAs that are positively (green) and
negatively (pink) correlated with age in each RNA type (row). (C) Disease classes (rows) that are associated with age-correlated exRNA genes; x axis, adjusted
P value from association tests. (D) Scatter plot of exRNA age (x axis) and chronological age (y axis) for every sample (circle).
known genes (60,675 genes, hg38) (SI Appendix, Fig. S11A).
Cancer and noncancer samples were not distinguishable by
the first principal component (PC1), but they exhibited some
extent of separation on the second principal component (PC2)
(SI Appendix, Fig. S11A). These data suggest not only large
sample-to-sample variations, but also the possible separation of
cancer and noncancer samples by some subspaces (subsets of
genes). This global feature is not sensitive to the number
of exRNAs used for PCA analysis (SI Appendix, Fig. S11 B
and C).
We proceeded to test whether the degrees of cancer-normal
separation are similar across different types of RNAs. To this
end, we did a PCA analysis with each type of RNA. Three classes
of RNA types emerged based on the capacity of their principal
components to explain cancer-normal differences. The first class
failed to separate cancer and normal samples by either PC1 or
PC2 (SI Appendix, Fig. S12A). The second class exhibited some
differentiation capability in PC2 but not in PC1 (SI Appendix,
Fig. S12B). This class, which included protein-coding transcripts,
processed pseudogenes, lincRNAs, and others, reflects the base-
line (SI Appendix, Fig. S11) in that, although cancer-normal dif-
ferences contributed to explain sample difference, it was not the
major contributor to sample variations (PC1). The third class was
able to differentiate cancer and normal samples in both PC1 and
PC2. This class included miRNA, mitochondrial transfer RNA
(Mt tRNA), ribosomal RNA (rRNA), and other noncoding
RNA (misc RNA). With the third class, the major contributor to
sample variation is the cancer/noncancer status. Taken together,
cancer and noncancer samples are well separated in some sub-
spaces, including the subspaces defined by the miRNAs and
Mt tRNAs.
Classifying Cancer and Normal Samples without Preselecting Differ-
entially Expressed exRNAs. We asked to what extent the cancer
and normal sera could be correctly classified by SILVER-seq
data. First, we used the 1,719 differentially expressed exRNAs
(|log2(fold change)| >2 and FDR < 0.05) as the feature set. All
cancer and normal serum samples were correctly classified by
a supporting vector machine (SVM) with 100 cross-validations
(average area under curve [AUC] = 1.0).
To avoid overfitting, we asked whether sera from cancer
patients and normal donors can be classified without using dif-
ferentially expressed exRNAs as features. To this end, we used
all of the annotated genes in the human genome. The human
genes were classified by their RNA type (also called biotype) into
protein coding, pseudogene, and noncoding genes, which were
further categorized into 17 subtypes, including antisense, lin-
cRNA, miRNA, and small nuclear RNA (snRNA) (20). We used
all of the RNAs of each biotype as a feature set to carry out classi-
fication with random forest (SI Appendix, Fig. S13) and SVM (SI
Appendix, Fig. S14). The different RNA types exhibited different
classification performances. Several transcript categories, includ-
ing small Cajal body-specific RNA (scaRNA) and polymorphic
pseudogene, failed to classify cancer and normal samples (Fig.
4 H and I and SI Appendix, Figs. S13 and S14). On the other
hand, using lincRNA and miRNA as feature sets improved clas-
sification performances (Fig. 4 J and K). In particular, miRNAs
as a feature set nearly perfectly classified cancer and normal
19204 | www.pnas.org/cgi/doi/10.1073/pnas.1908252116 Zhou et al.
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Fig. 4. The exRNA expression in cancer and normal serum samples. (A) Distribution of exRNA expression levels of every gene in the human genome (60,675
genes in total, hg38) in 2 representative cancer samples (C10, C86) and 2 representative normal samples (N9, N15). See SI Appendix, Fig. S9 for all other
samples. (B) Volcano plot of log fold change (cancer/normal) (x axis) and FDR (y axis) for all exRNAs (dots). (C–G) Expression levels of (C) RAC2, (D) KRAS, (E)
CAMK2A, and (F) AL121652.1 and (G) AC048346.1 exRNA in cancer (red) and normal serum (blue). (H–K) receiver operating characteristic (ROC) curves of
classification results based on (H) scaRNA, (I) polymorphic pseudogene, (J) lincRNA, and (K) miRNA, based on 3-fold cross-validations (red, green, blue).
samples (Fig. 4K). These classification results independent of
preselected differentially expressed exRNAs suggest that the
cancer-normal differences are an intrinsic characteristic of the
circulating extracellular transcriptome.
Difference between Patients with and without Cancer Recurrence.
We tested whether there is any difference in exRNA expres-
sion that may correspond to cancer recurrence. The 96 analyzed
serum samples were collected from breast cancer patients dur-
ing a 5-y follow-up starting from their chemotherapy start date.
Among them, 28 and 68 samples were collected from patients
who developed and did not develop recurring cancer, respec-
tively, in the 5-y follow-up; these 2 groups of serum samples
will be referred to as recurrence and nonrecurrence samples,
respectively. No exRNA was called as differentially expressed
at the significance level of FDR = 0.1, suggesting that the
difference between recurrence and nonrecurrence samples is
more obscure than the difference between cancer and nor-
mal serum samples. Nevertheless, based on 2,230 exRNAs that
exhibited fold changes of 2 or greater, recurrence and nonrecur-
rence samples could be accurately classified (AUC > 0.999, 100
cross-validations).
To avoid overfitting, we proceeded with classifications with-
out using differentially expressed exRNAs. First, we used all of
the genes of each RNA biotype, including mRNA, lincRNA,
miRNA, and others (20). As expected, the cross-validation
AUCs were close to 0.5 for most of the RNA biotypes (SI
Appendix, Figs. S15 and S16), consistent with the idea that recur-
rence and nonrecurrence samples were less separated than can-
cer and normal samples. Nevertheless, classifications based on
several RNA biotypes, including unprocessed pseudogene (21)
and lincRNA, resulted in better AUCs than random guesses in
cross-validations (Fig. 5 A and B). These data suggest a moderate
separation of recurrence and nonrecurrence samples.
Next, we compiled a list of 750 genes that were associated
with breast cancer by prior literature (prior-association genes)
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Fig. 5. Classification of serum samples from patients with or without cancer recurrence. (A and B) Representative ROC curves from cross-validations, using
all of the genes of each RNA type as features, including (A) unprocessed pseudogenes and (B) lincRNAs. (C and D) Classifications based on prior-association
genes. (C) Average AUC of 100 cross-validations (y axis) based each number of prior-association genes used as features (x axis). (D) Representative ROC
curves from 100 cross-validation based on 215 prior-association genes as features.
(SI Appendix, Table S5). This mixed group of genes were asso-
ciated with breast cancer in many ways, including genotype–
disease association and the associations of gene expression in
cancer biopsy and cancer subtypes, grades, or prognoses. When
this mixed bag of literature-derived genes was used as the feature
set, an SVM classifier was able to better distinguish recurrence
and nonrecurrence samples (average AUC = 0.720) than using
the genes of any biotype (maximum average AUC = 0.696)
(SI Appendix, Figs. S15 and S16). These data suggest that the
exRNA expression of the prior-association genes was correlated
with recurrence status, even though the prior association was not
discovered using exRNA expression.
When we varied the number of prior-association genes in the
feature set, the classification performance peaked between 150
and 400 genes and decreased when either fewer or more prior-
association genes were used (Fig. 5C). For example, using 215
prior-association genes as the feature set, the average AUC
reached 0.978 in 100 cross-validations (Fig. 5D). These data
support that exRNA expression contains information about the
recurrence status in breast cancer patients. However, such infor-
mation likely resides in a combination of exRNAs rather than in
any individual exRNA.
Discussion
Breaking the Bottleneck of Input Volume for Serum exRNA Sequenc-
ing. The standard input volume for serum exRNA sequencing
analysis is several milliliters (4, 22, 23). Smaller input volume
would result in too little RNA after the RNA extraction step. To
overcome this bottleneck, we recognized that an enabling step in
the transformation from bulk-cell RNA sequencing to single-cell
RNA sequencing was to skip RNA extraction and directly carry
out complementary DNA (cDNA) synthesis in cell lysis solution
(9, 24). This idea prompted us to test exRNA sequencing from
ultralow input of serum by cDNA synthesis in serum lysis solu-
tion without RNA extraction, which became the central ideal of
SILVER-seq.
Even with plenty of (milliliters) serum as input, large measure-
ment variations of exRNA from sequencing have been reported
(22, 25). Despite these variations, the relative abundances of dif-
ferent exRNAs were, to some extent, comparable across different
exRNA sequencing methods (22, 25). Importantly, the correla-
tion between 2 standard RNA-seq datasets was comparable to
that between a SILVER-seq and a standard RNA-seq, as well
as that between 2 SILVER-seq datasets. These results indicate
that SILVER-seq effectively restrained additional measurement
variations due to the decrease of input volume.
We suspect that the biological variation in exRNA content
between 2 serum droplets is primarily attributable to the dif-
ferent composition of exRNA carriers. These carriers include
extracellular vesicles (EVs), RNPs, lipoprotein complexes (22),
nonmembranous nanoparticles (exomeres) (26), and other to-
be-identified types. It would require future technology develop-
ments to quantify the variability of cargo composition between 2
serum samples, especially between 2 small-volume samples.
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Fragments of Long RNAs in Human Serum. Most previous analy-
ses focused on small RNAs (4, 22, 25). However, up to 55%
of serum-extracted RNA sequences could not be aligned to
small RNAs (22), begging the question of what other RNAs
are present in human sera. SILVER-seq revealed large amounts
of long RNA fragments in human sera. These fragments were
typically 200 nt or smaller in length. They were derived from
mRNAs, lncRNAs, and pseudogene RNAs. The host RNAs of
these fragments could exhibit tissue specificity in expression. As
a result, the majority of tissue-specific RNAs, including brain-
specific RNAs, were detectable in human serum as fragments.
Some of these fragments derived from cancer-related genes,
including KRAS, were among the most upregulated exRNAs
in cancer patients as compared to normal donors. These data
suggest the value of including RNA fragments in future liquid
biopsy-based IVD research.
Serum exRNA Reflects Sex and Age. We hypothesized exRNA
in serum reflects differences based on a donor’s age and
sex. However, a recent analysis reported a counterintuitive
observation that the sex-associated exRNAs in human serum
were not expressed from the sex chromosomes (22). There
is, as yet, no literature on testing the association of any
biofluid exRNA to age. This study reported a strong asso-
ciation of sex chromosome-derived exRNAs with donor’s
sex, and a strong association of several hundred exRNAs
to donor’s chronological ages (Fig. 3). Furthermore, the age-
associated exRNAs overlapped with the previously identified
genes with age-dependent expression in various tissues and were
enriched for the genes associated with age-related disorders.
These data support using exRNA to monitor human physiology.
This study only analyzed donors between 18 y and 48 y old.
The identified age-associated exRNAs are probably specific to
this age group and cannot be extrapolated to older ages. For
example, the genes involved in substance dependence and psy-
chological disorders (Fig. 3C) are primarily expressed in brain.
Gene expression changes in adolescent and adult brains are
associated with different vulnerabilities for substance addition
(27–30). Thus, this subset of age-related exRNAs may have
reflected the changes of the brain between early and middle
adulthood.
The Differentiating Power of miRNAs and Mt tRNAs to Classify Breast
Cancer Patients and Normal Donors. A common practice to avoid
overfitting is to subject the biomarkers developed from one
patient cohort to validation in another cohort. However, there is
only one cohort in this study. To minimize overfitting in this sce-
nario, we did not use the common practice of using differentially
expressed exRNAs as features for classification. Instead, we used
the entire list of genes of each gene category (protein coding,
lincRNA, antisense, miRNA, etc.) as a feature set to classifica-
tion. This approach tested whether the exRNAs of each gene
category as a whole contain any information on the disease sta-
tus. Interestingly, miRNAs and Mt tRNAs exhibited the largest
differentiating powers to classify breast cancer patients and nor-
mal donors. These data expanded the previously reported clinical
variables that correlate with serum/plasma miRNAs (6, 7). These
data also nominate serum extracellular Mt tRNAs as another
prominent class of molecules in developing clinically relevant
biomarkers.
Limitations of This Study. Breast cancers include several molec-
ular subtypes. This study included 10, 48, 12, and 26 samples
from Her2-enriched, luminal A or normal-like, luminal B, and
triple-negative subtypes, respectively (SI Appendix, Table S4).
The top 100 exRNAs that were most correlated with subtype
differences (ANOVA, q value ranges from 0.055 to 0.999)
included ODC1 (31), RBP3 (32), and WIF1 (33) that were
also differentially expressed in the tissue biopsies between
these subtypes (SI Appendix, Fig. S17). Thus, exRNA expres-
sion may reflect the differences between different subtypes
of breast cancer. However, the small number of samples in
each subtype is insufficient to assess the significance of such
correlations.
This study did not rule out all possible confounding factors that
may contribute the separation of cancer and normal samples.
Most of the serum samples from cancer patients were collected
during or after chemotherapy (SI Appendix, Table S4). Thus,
this study cannot separate chemotherapy-induced changes from
cancer-induced changes. However, the consistent upregulation
of RAC2 and KRAS exRNAs in serum and mRNAs in tissue in
breast cancer patients as compared to normal donors, together
with the known roles of these 2 members of the Ras proto-
oncogene superfamily in breast cancer etiology, suggest that a
subset of the observed serum exRNA expression changes relate
to the disease rather than the treatments. Future studies that
control for treatment status and cancer subtypes are needed,
preferably as double-blind prospective trials.
Materials and Methods
Human Serum Samples. Obtaining and analysis of deidentified human sera
has been approved by University of California San Diego Human Research
Protections Program.
Analysis of Sizes of exRNAs in Serum. A total of 9 serum samples of 1-mL
volume were analyzed (samples 1 to 9, SI Appendix, Fig. S1). RNA of each
sample was purified by one of the 3 kits, namely, exoRNeasy Serum/Plasma
Midi Kit (QIAGEN), TRIzol LS Reagent (Invitrogen), or Plasma/Serum RNA
Purification Kit (NORGEN). The RNA extracted with the NORGEN kit was
treated with RNase-Free DNase I (QIAGEN) and RNeasy MinElute Cleanup Kit
(QIAGEN) according to manufacturer’s instruction. Another serum sample
of 200-µL volume was also analyzed (sample 10; SI Appendix, Fig. S1). RNA
from this sample was purified with the QIAzol (QIAGEN) kit. Extracted RNA
was stored at −80 ◦C until use. RNA sizes were analyzed by the bioanalyzer
RNA pico chip (Agilent).
Construction of SILVER-seq Sequencing Libraries. The starting volume of each
serum sample was between 3 µL and 7 µL. Any serum sample of vol-
ume smaller than 7 µL was supplemented with Ultrapure water to reach
a total volume of 7 µL. EVs were lysed, and RNPs were disassociated
by mixing the sample with 1.7 µL of 11.5 mM DTT solution, 0.5 µL of
40 U/µL RNase inhibitor, and 2.8 µL of lysis buffer consisting of 10 mM
Tris-HCl, 0.2% w/v SDS solution, and 4% w/v Nonidet P-40. First- and
second-strand cDNA syntheses were carried out as follows (SI Appendix, Fig.
S2) (https://www.genemo.com/technology/silver-seq). The resulting material
from the previous step was incubated with a mix of random hexamer and
oligo-dT primers at 70 ◦C for 2 min, and incubated with temperature-
sensitive double-strand DNase (HL-dsDNase) at 37 ◦C for 10 min, then at
65 ◦C for 5 min for enzyme deactivation, and subsequently incubated with
reverse transcriptase at 25 ◦C for 5 min followed by 40 ◦C for 30 min and
70 ◦C for 10 min. The resulting material was incubated with DNA poly-
merase and template-switching oligo at 25 ◦C for 15 min, at 37 ◦C for
15 min, and then 70 ◦C for 10 min and subjected to end repair, adap-
tor ligation, size selection, amplification, and rRNA sequence depletion
(https://www.genemo.com/technology/silver-seq). The product library was
quantified with Qubit (Invitrogen), and measured by Bioanalyzer (Agilent)
for size distribution.
Alignment to Reference Genome. STAR (STAR 2.5.1b, default parameters)
was used to align SILVER-seq and RNA-seq reads to the reference genome
(hg38). Uniquely aligned reads were used together with the gene anno-
tation file (Hg38/Ensembl) as input files to HTSeq-count (version 0.9.1)
to count the number of reads per gene, which was subsequently trans-
formed in TPM.
Association Analysis of exRNA and Chronological Age. F test was used to test
the correlation of the TPM of every exRNA with chronological age. The F
test-derived P values were provided to the R package {qvalue} to calculate
q values. The chronological age and the top 500 exRNAs with the largest
Pearson correlation with age were given to the R package {glmnet} to fit a
linear regression with elastic net regularization.
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Calculating the Frequency of Detecting an exRNA. An exRNA is called
detected in a sample at the threshold of TPM > 5. The frequency of detect-
ing an exRNA among the samples was calculated as the proportion of
samples in which this exRNA was detected.
Gene Categories and RNA Types. The gene categories as defined by Ensembl
were used in PCA and classification analyses. Ensembl categorized genes by
their RNA types, also called RNA biotypes. A total of 23 gene categories
contained at least 10 genes per category, which included protein coding,
lincRNA, miRNA, snRNA, and other biotypes.
Classification Analysis. Classification of cancer samples including both recur-
rence and nonrecurrence samples and noncancer samples was carried out
with both random forest and linear kernel SVM using R package {mlr} (34).
Each feature set was defined as all of the exRNAs of each gene category.
The log-transformed TPMs (log2(TPM+1)) of every exRNA were given as the
input data. Threefold cross-validations were carried out unless otherwise
stated.
Classification of recurrence and nonrecurrence cancer samples were car-
ried out using the same procedure as that used for classification of cancer
and noncancer samples. In addition, all analyses were repeated using the
prior-association genes (SI Appendix, Table S5) as a feature set.
ACKNOWLEDGMENTS. This work is funded, in part, by American Cancer
Society grant MRSG-08-110-01-CCE and National Institutes of Health grants
HD058799, HL106579, and HL108735. We thank Drs. Shu Xiao, Jerry Skefos,
Tri C. Nguyen, and Bharat Sridhar for useful discussions.
1. E. Heitzer, I. S. Haque, C. E. S. Roberts, M. R. Speicher, Current and future perspectives
of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).
2. S. Alimirzaie, M. Bagherzadeh, M. R. Akbari, Liquid biopsy in breast cancer: A
comprehensive review. Clin. Genet. 95, 643–660 (2019).
3. J. C. H. Tsang et al., Integrative single-cell and cell-free plasma RNA transcriptomics
elucidates placental cellular dynamics. Proc. Natl. Acad. Sci. U.S.A. 114, E7786–E7795
(2017).
4. O. D. Murillo et al., ExRNA atlas analysis reveals distinct extracellular RNA cargo types
and their carriers present across human biofluids. Cell 177, 463–477 e15 (2019).
5. J. E. Freedman et al., Diverse human extracellular RNAs are widely detected in human
plasma. Nat. Commun. 7, 11106 (2016).
6. K. E. A. Max et al., Human plasma and serum extracellular small RNA reference
profiles and their clinical utility. Proc. Natl. Acad. Sci. U.S.A. 115, E5334–E5343
(2018).
7. Y. M. Lo, Noninvasive prenatal diagnosis: From dream to reality. Clin. Chem. 61, 32–37
(2015).
8. ClinicalTrials.gov, Predictors of ovarian insufficiency in young breast cancer patients
(POISE). https://clinicaltrials.gov/ct2/show/NCT01197456. Accessed 30 April 2017.
9. D. Ramskold et al., Full-length mRNA-seq from single-cell levels of RNA and individual
circulating tumor cells. Nat. Biotechnol. 30, 777–782 (2012).
10. N. Wang et al., Single-cell microRNA-mRNA co-sequencing reveals non-genetic
heterogeneity and mechanisms of microrna regulation. Nat. Commun. 10, 95
(2019).
11. H. Kempe, A. Schwabe, F. Cremazy, P. J. Verschure, F. J. Bruggeman, The volumes
and transcript counts of single cells reveal concentration homeostasis and capture
biological noise. Mol. Biol. Cell 26, 797–804 (2015).
12. J. Wang et al., Gene expression distribution deconvolution in single-cell RNA
sequencing. Proc. Natl. Acad. Sci. U.S.A. 115, E6437–E6446 (2018).
13. G. K. Marinov et al., From single-cell to cell-pool transcriptomes: Stochasticity in gene
expression and RNA splicing. Genome Res. 24, 496–510 (2014).
14. J. D. Cahoy et al., A transcriptome database for astrocytes, neurons, and oligodendro-
cytes: A new resource for understanding brain development and function. J. Neurosci.
28, 264–278 (2008).
15. X. Liu, X. Yu, D. J. Zack, H. Zhu, J. Qian, TIGER: A database for tissue-specific gene
expression and regulation. BMC Bioinf. 9, 271 (2008).
16. W. Huang da, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57
(2009).
17. J. Kristic et al., Glycans are a novel biomarker of chronological and biological ages. J.
Gerontol. A Biol. Sci. Med. Sci. 69, 779–789 (2014).
18. E. Wertheimer et al., Rac signaling in breast cancer: A tale of GEFs and GAPs. Cell.
Signal. 24, 353–362 (2012).
19. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57–70 (2000).
20. D. R. Zerbino et al., Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).
21. M. Suyama, E. Harrington, P. Bork, D. Torrents, Identification and analysis of genes
and pseudogenes within duplicated regions in the human and mouse genomes. PLoS
Comput. Biol. 2, e76 (2006).
22. S. Srinivasan et al., Small RNA sequencing across diverse biofluids identifies optimal
methods for exRNA isolation. Cell 177, 446–462 e16 (2019).
23. A. Yeri et al., Evaluation of commercially available small RNASeq library preparation
kits using low input RNA. BMC Genomics 19, 331 (2018).
24. F. Tang et al., mRNA-seq whole-transcriptome analysis of a single cell. Nat. Methods
6, 377–382 (2009).
25. M. D. Giraldez et al., Comprehensive multi-center assessment of small RNA-seq
methods for quantitative mirna profiling. Nat. Biotechnol. 36, 746–757 (2018).
26. H. Zhang et al., Identification of distinct nanoparticles and subsets of extracellu-
lar vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343
(2018).
27. F. Crews, J. He, C. Hodge, Adolescent cortical development: A critical period of
vulnerability for addiction. Pharmacol. Biochem. Behav. 86, 189–199 (2007).
28. S. Bava, S. F. Tapert, Adolescent brain development and the risk for alcohol and other
drug problems. Neuropsychol. Rev. 20, 398–413 (2010).
29. B. J. Casey, R. M. Jones, Neurobiology of the adolescent brain and behavior: Implica-
tions for substance use disorders. J. Am. Acad. Child Adolesc. Psychiatry 49, 1189–1201
(2010).
30. M. Arain et al., Maturation of the adolescent brain. Neuropsychiatr. Dis. Treat. 9,
449–461 (2013).
31. P. Zubor et al., Gene expression abnormalities in histologically normal breast epithe-
lium from patients with luminal type of breast cancer. Mol. Biol. Rep. 42, 977–988
(2015).
32. E. K. Shanle et al., Research resource: Global identification of estrogen receptor beta
target genes in triple negative breast cancer cells. Mol. Endocrinol. 27, 1762–1775
(2013).
33. S. G. Pohl et al., Wnt signaling in triple-negative breast cancer. Oncogenesis 6, e310
(2017).
34. B. Bischl et al., mlr: Machine learning in R. J. Mach. Learn. Res. 17, 5938–5942 (2016).
19208 | www.pnas.org/cgi/doi/10.1073/pnas.1908252116 Zhou et al.
